Phaos Technology registers up to 406,808 shares for resale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Phaos Technology Holdings (Cayman) Limited (POAS) registered up to 406,808 Class A ordinary shares for resale by High West Partners LLC, comprising up to 365,486 Purchase Shares Phaos may elect to sell to High West and 41,322 Commitment Shares. Phaos receives no proceeds from High West’s resales or cash from issuing Commitment Shares, but may receive up to US$10,000,000 in gross proceeds from Purchase Share sales it elects to make under the agreement, subject to its terms. A 4.99% beneficial ownership limit may be increased to no more than 9.99%, effective on the 61st day after notice.
Annual revenue declined to S$132,077 for the year ended April 30, 2026, from S$167,707 in fiscal 2025; net loss increased to S$6,157,779 from S$5,137,064. Phaos assembles and commercializes microscopy systems, including super-resolution imaging down to 137 nm, and related software. Class B shares carry 20 votes per share, compared with one vote per Class A share.
Filing Explained
This November 20 F-1 remains preliminary: Phaos cannot begin selling under the facility until the registration statement is effective and the agreement’s other start conditions are met. The filing itself issues no shares; any later Purchase Shares Phaos elects to issue would add dilution for existing holders.
Key Figures
Key Terms
VWAP Purchases financial
Beneficial Ownership Limitation financial
Exchange Cap regulatory
microsphere-assisted technology technical
optical diffraction limit technical
DWAC technical
Offering Details
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many POAS shares can High West Partners LLC resell?
How much could Phaos receive from the POAS purchase agreement?
How is the price for POAS VWAP purchases calculated?
What ownership limit applies to High West’s POAS purchases?
AI-generated analysis. How Rhea-AI works. Not financial advice.
As filed with the U.S. Securities and Exchange Commission on November 20, 2026.
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM F-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Phaos Technology Holdings (Cayman) Limited
(Exact name of registrant as specified in its charter)
| Cayman Islands | 3823 | Not Applicable | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification Number) |
55 Ayer Rajah Crescent #05-05
Singapore 139949
+65 6224 6320
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Cogency Global Inc.
122 East 42nd Street, 18th Floor
New York, New York 10168
800-221-0102
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Lawrence Venick, Esq. Loeb & Loeb LLP 10100 Santa Monica Blvd #2200, Los Angeles, CA 90067 Telephone: 310-728-5129 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act of 1933, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Emerging growth company ☒
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
| † | The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. |
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as the U.S. Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The information in this prospectus is not complete and may be changed. We may not sell the securities until the registration statement filed with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.
| PRELIMINARY PROSPECTUS | SUBJECT TO COMPLETION, DATED NOVEMBER 20, 2026 |

Phaos Technology Holdings (Cayman) Limited
Up to 406,808 Class A Ordinary Shares to be Sold by the Selling Shareholder
This prospectus relates to the resale from time to time by High West Partners LLC, a California limited liability company (“High West” or the “Selling Shareholder”), of up to 406,808 Class A ordinary shares, par value US$0.0015 per share (“Class A Ordinary Shares”), of Phaos Technology Holdings (Cayman) Limited, an exempted company incorporated in the Cayman Islands (“we,” “us,” “our,” or the “Company”), issuable pursuant to the securities purchase agreement, dated as of September 28, 2026, by and between us and High West (the “Purchase Agreement”). Such Class A Ordinary Shares include (i) up to the greater of an amount of shares equal to the Exchange Cap (as defined in the Purchase Agreement) or $10,000,000 of the Company’s Class A Ordinary Shares pursuant to the Purchase Agreement (such shares, the “Purchase Shares”), and (ii) $100,000 of the Company’s Class A Ordinary Shares issuable to High West as a commitment fee (the “Commitment Shares”).
The actual number of Purchase Shares issuable under the Purchase Agreement will depend on the purchase prices and other terms of any Single Day Purchases and VWAP Purchases. The number of Commitment Shares issuable under the Purchase Agreement equals US$100,000 divided by the closing price of the Class A Ordinary Shares on the Commitment Shares Determination Date, which is the earlier of the business day preceding the effectiveness of the registration statement and the business day preceding High West’s written request for issuance of the Commitment Shares. Accordingly, the aggregate number of Purchase Shares and Commitment Shares issuable may be more or less than the number of Class A Ordinary Shares being registered for resale under this prospectus. If we issue and sell shares at prices lower than the assumed price used for purposes of this prospectus, we may be required to file additional registration statement(s) to register the resale of additional shares, and such registration statement(s) would be required to be declared effective by the SEC.
From and after the Commencement Date, subject to the terms and conditions of the Purchase Agreement, we may, in our sole discretion, direct High West to purchase Class A Ordinary Shares through Single Day Purchases or VWAP Purchases by delivering the applicable purchase notice. The purchase price per share for each Single Day Purchase equals the average of the three lowest traded prices of the Class A Ordinary Shares on the applicable Single Day Purchase Date. The purchase price per share for each VWAP Purchase equals 97% of the lowest daily volume-weighted average price of the Class A Ordinary Shares during the three consecutive trading days beginning on the date High West receives the applicable VWAP Purchase Notice, in each case subject to adjustment as provided in the Purchase Agreement.
Each purchase is subject to certain limitations and conditions under the Purchase Agreement. The maximum number of shares for each Single Day Purchase is generally the lesser of (i) 40% of the three-day average daily trading volume and (ii) US$1,000,000, subject to increase by mutual consent, divided by the highest closing sale price of the Class A Ordinary Shares during the five trading days immediately preceding receipt of the purchase notice. The maximum number of shares for each VWAP Purchase is generally 200% of the average daily trading volume during the five trading days preceding High West’s receipt of the applicable VWAP Purchase Notice. The aggregate purchase amount for VWAP Purchases on a particular VWAP Purchase Date may not exceed the applicable US$1,000,000 investment limit unless waived by High West as provided in the Purchase Agreement. These purchases are also subject to a beneficial ownership limitation that prohibits issuances that would cause High West and the other attribution parties specified in the Purchase Agreement to beneficially own more than 4.99% of our outstanding Class A Ordinary Shares immediately after issuance. High West may increase or decrease that percentage to a percentage not exceeding 9.99%, provided that an increase will not become effective until the 61st day after notice to us.
In connection with entering into the Purchase Agreement, we agreed to issue the Commitment Shares and reimburse High West for US$15,000 of its legal fees. We may elect to satisfy that reimbursement through a deduction from the proceeds of the first purchase under the Purchase Agreement. We also agreed to pay the clearing costs associated with each purchase notice and any transfer agent fees incurred by High West.
Unless earlier terminated in accordance with its terms, the Purchase Agreement will expire on the first day of the month immediately following the 36-month anniversary of the Commencement Date. The Purchase Agreement also provides for automatic termination upon specified events and permits us to terminate it for any reason upon at least one trading day’s prior written notice, subject to its terms.
We are not selling any securities under this prospectus and will not receive any of the proceeds from the sale of Class A Ordinary Shares by the Selling Shareholder. We will not receive any cash proceeds from the issuance of the Commitment Shares. However, we may receive up to US$10,000,000 in aggregate gross proceeds from sales of Purchase Shares that we may elect to make to High West pursuant to the Purchase Agreement after the Commencement. See “High West Partners LLC Committed Equity Financing” for a description of the Purchase Agreement and “Selling Shareholder” for additional information regarding High West.
We will pay the expenses of registering the resale of the Class A Ordinary Shares offered by this prospectus. The Selling Shareholder will bear any sales or brokerage commissions incurred in connection with its resales. The Selling Shareholder may sell the Class A Ordinary Shares offered by this prospectus from time to time on terms to be determined at the time of sale through ordinary brokerage transactions or through any other means described under “Plan of Distribution.” The prices at which the Selling Shareholder may sell shares will be prevailing market prices, prices related to prevailing market prices or privately negotiated prices.
High West is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities Act”), and any profits on sales of Class A Ordinary Shares by High West and any discounts, commissions or concessions received by High West will be deemed to be underwriting discounts and commissions under the Securities Act.
We are an “Emerging Growth Company” and a “Foreign Private Issuer” under applicable U.S. federal securities laws and, as such, are eligible for reduced public company reporting requirements. Please see “Implications of Being an Emerging Growth Company” and “Implications of Being a Foreign Private Issuer” beginning on page 8 and 9 for more information.
We are a holding company that is incorporated in the Cayman Islands. As a holding company with no operations, we conduct all of our operations through our wholly owned subsidiaries in Singapore. The Class A Ordinary Shares offered in this offering are shares of the holding company that is incorporated in the Cayman Islands.
Our dual class share structure consists of Class A Ordinary Shares, which are entitled to one (1) vote per share and Class B Ordinary Shares, which are entitled to twenty (20) votes per share. Our Class B Ordinary Share is convertible, at the option of the holder thereof, into one Class A Ordinary Share, subject to the terms of our third amended and restated memorandum and articles of association. Our Class A Ordinary Shares are not convertible into our Class B Ordinary Shares under any circumstances. Only our Class A ordinary shares are tradable on the NYSE American under the symbol “POAS”. This voting structure may discourage investors from pursuing any change of control transactions that holders of our Class A Ordinary Shares may view as beneficial.
The information contained or incorporated in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities.
Investing in our securities being offered pursuant to this prospectus involves a high degree of risk. You should carefully read and consider the “Risk Factors’’ section of this prospectus, and risk factors set forth in our most recent annual report on Form 20-F, in other reports incorporated herein by reference, and in the applicable prospectus supplement before you make your investment decision.
Neither the U.S. Securities and Exchange Commission, the Cayman Islands Monetary Authority, nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
TABLE OF CONTENTS
| Page | ||
| ABOUT THIS PROSPECTUS | 1 | |
| PROSPECTUS SUMMARY | 2 | |
| THE OFFERING | 10 | |
| RISK FACTORS | 11 | |
| SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS | 13 | |
| USE OF PROCEEDS | 14 | |
| DIVIDEND POLICY | 14 | |
| MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 15 | |
| PRINCIPAL SHAREHOLDERS | 15 | |
| HIGH WEST PARTNERS LLC COMMITTED EQUITY FINANCING | 17 | |
| SELLING SHAREHOLDER | 20 | |
| DESCRIPTION OF SECURITIES WE ARE OFFERING | 22 | |
| ENFORCEABILITY OF CIVIL LIABILITIES | 24 | |
| PLAN OF DISTRIBUTION | 24 | |
| EXPENSES RELATING TO THIS OFFERING | 25 | |
| LEGAL MATTERS | 25 | |
| EXPERTS | 25 | |
| INCORPORATION OF CERTAIN INFORMATION BY REFERENCE | 26 | |
| WHERE YOU CAN FIND MORE INFORMATION | 26 |
You should rely only on the information provided in this prospectus and any applicable prospectus supplement. Neither we nor the Selling Shareholder have authorized anyone to provide you with different information. Neither we nor the Selling Shareholder are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus and any applicable prospectus supplement is accurate as of any date other than the date of the applicable document. Since the respective dates of this prospectus, our business, financial condition, results of operations, and prospects may have changed.
| i |
ABOUT THIS PROSPECTUS
This prospectus is part of a registration statement on Form F-1 that we filed with the SEC using a continuous offering process. Under this continuous offering process, High West Partners LLC, the Selling Shareholder, may, from time to time, offer and sell up to an aggregate of 406,808 Class A Ordinary Shares, consisting of Purchase Shares and Commitment Shares issued or issuable pursuant to the Purchase Agreement, as described in the section titled “Plan of Distribution.”
You should read this prospectus, exhibits filed as part of the registration statement, and the information and documents incorporated by reference carefully. Such documents contain important information you should consider when making your investment decision. See “Where You Can Find More Information” in this prospectus.
You should rely only on the information provided in this prospectus, exhibits filed as part of the registration statement, or documents incorporated by reference into this prospectus. We have not authorized anyone to provide you with different information. This prospectus covers offers and sales of our Class A Ordinary Shares only in jurisdictions in which such offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our Class A Ordinary Shares. You should not assume that the information contained in this prospectus is accurate as of any date other than the date on the front cover of this prospectus, or that the information contained in any document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any sale of our Class A Ordinary Shares.
This prospectus may be supplemented from time to time to add, update, or change information in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in a prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus.
| 1 |
PROSPECTUS SUMMARY
This summary highlights information contained elsewhere in this prospectus. This summary may not contain all of the information that may be important to you, and we urge you to read this entire prospectus carefully, including the “Risk Factors,” “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections and our consolidated financial statements and notes to those statements, included elsewhere in this prospectus, before deciding to invest in our Class A Ordinary Shares. This prospectus includes forward-looking statements that involve risks and uncertainties. See “Special Note Regarding Forward-Looking Statements.”
Overview
Phaos Technology Holdings (Cayman) Limited (the “Company”) is an investment holding company incorporated on March 7, 2024, under the laws of the Cayman Islands. The Company through its subsidiary assembles and commercializes such advanced microscopy-related solutions, technologies and products.
Our business is primarily involved in the assembling and commercialization of advanced microscopy-related solutions, technologies and products tailored for precision measurement and magnification purposes. Our product range includes microscopy solutions, featuring:
| i) | Super-resolution imagers capable of achieving imaging down to 137 nm; | |
| ii) | Specialized microscopes designed to meet the diverse needs of various industries; and | |
| iii) | Three-dimensional (“3-D”) real-time image magnifiers for enhanced visualization. |
Traditional optical microscopes are generally limited by the diffraction properties and wave nature of light, which create a physical resolution barrier commonly referred to as the optical diffraction limit. As a result of this limitation, conventional optical microscopes are typically unable to distinguish two closely spaced objects as separate features below approximately 200nm, regardless of magnification.
Existing alternatives used to overcome this limitation, such as electron microscopy, generally require vacuum operating conditions, complex sample preparation processes and extremely short working distances, which may limit their practical use in routine industrial, research and clinical settings.
Using its patented microsphere-assisted technology, the Company integrates a precision-engineered transparent microsphere lens into the optical path of a conventional optical microscope, which significantly increases magnification and imaging resolution capabilities compared to traditional optical microscopy systems. This technology enables users to visualize features below the conventional optical diffraction limit of approximately 200nm under ambient laboratory conditions, with imaging resolution down to 137nm.
Our systems are designed to maintain a commercially viable working distance, meaning that they are capable of imaging samples without requiring vacuum operating conditions, extensive sample preparation or the extremely short working distances commonly associated with alternative high-resolution imaging technologies, such as electron microscopy. We believe our products are capable of imaging below the 200nm optical limit while maintaining practical working distances suitable for industrial and research applications.
In addition to our hardware offerings, we provide complementary proprietary software developed entirely in-house to complement our microscopy solutions and facilitate integration, automation and operational efficiency for our customers.
Our software includes Artificial Intelligence (“AI”) components that utilize computer vision and machine learning algorithms to support image-based defect detection, recognition pattern analysis, research applications, quality assurance and quality control (“QA/QC”), and diagnostics-related functions. The AI-assisted visual inspection solution is trained using customer-supplied inspection images and quality feedback to establish a baseline AI model tailored to each customer’s products, inspection standards and defect identification requirements.
During the initial deployment phase, the AI model operates concurrently with customer personnel by generating a preliminary inspection classification of “Pass,” “Suspect,” or “Fail.” Customer operators independently review the AI-generated classifications and provide feedback to refine and improve the model over time. We expect the continuous learning process to require approximately six months to achieve a stable level of accuracy, although performance may continue to improve as additional inspection data is collected and incorporated into the model.
Our AI models and related applications are deployed on customized machines designed specifically for customers with specialized QA/QC requirements. As a result, each deployment is configured based on the customer’s specific products, manufacturing environment and defect identification parameters.
To maintain data security and confidentiality, inspection images and AI-related data are stored on local servers maintained within the customer’s operating environment. The AI components described above are representative of our broader AI development approach across our customer base, and we expect our AI capabilities, training methodologies and performance metrics to continue evolving as additional customer projects are implemented.
For the years ended April 30, 2025 and April 30, 2026, the provision of microscopy products and components contributed to 95.9% and 91.8% of our revenue, respectively.
We distribute our microscopy products and software solutions through a combination of distributors and direct customer sales channels, primarily in Singapore and Indonesia, while continuing to expand across Southeast Asia and South Asia. In recent periods, we have implemented a sales channel diversification strategy focused on increasing direct engagement with end customers in order to strengthen brand recognition, diversify our customer base and reduce reliance on sales to distributors.
Our microscopy solutions accommodate a diverse range of applications enabling us to serve a wide range of customer needs and capitalize on emerging growth opportunities in the region. Our diverse customer base primarily includes industries with usage in fields such as manufacturing, research & development, biomedical, semiconductors, Printed Circuit Board (“PCB”), electronics, precision engineering, injection molding, research, healthcare, QA/QC and diagnostics. Our business strategic focus involves strengthening our market position in Singapore and Indonesia, and progressively expanding into the Southeast Asian region.
| 2 |
Revenue for the year ended April 30, 2026 was S$132,077, compared to S$167,707 for the year ended April 30, 2025. The decline in revenue was primarily attributable to delayed sales orders from our customers. During the same period, revenue concentration from our largest single customer increased from approximately 23% of total revenue to approximately 38%, while the contribution from our five largest customers decreased from approximately 85% to approximately 81% of total revenue.
Additional resources have been allocated to support our regional expansion strategy in Singapore and Malaysia in response to the reduction in sales orders from certain of our largest customers. Singapore remains our primary operating market, where we continue to strengthen commercial relationships and expand our customer base across the manufacturing, semiconductor, precision engineering, biomedical and research sectors. Malaysia represents our principal near-term expansion market, where we are establishing direct customer relationships and increasing our market presence across similar industry verticals. We continue to implement our direct sales strategy through direct engagement with end customers, led by our Managing Director, Mr. Tay Beng Boon, who works closely with customers to develop tailored solutions designed to address their operational requirements. We expect that our ongoing customer diversification and regional expansion efforts will allow us to increase and stabilize product sales over time through a broader customer base and reduced customer concentration.
In June 2025, the Company reduced its workforce from 25 to 10 full-time employees to align its cost structure with current operational needs following the decline in revenue for the year ended April 30, 2025. As a result of the workforce reduction and other cost management measures, the Company’s monthly operating expenses have been reduced to below S$200,000. Management believes that the workforce reduction has not adversely affected the Company’s ability to support its existing operations, attract or retain personnel, or continue implementing its direct sales strategy.
We believe our customer diversification and cost management initiatives have begun to produce initial operational improvements. For the year ended April 30, 2025, our revenue was S$167,707 (US$131,667), and our net loss and accumulated deficit were S$5,137,064 (US$4,033,109) and S$12,167,130 (US$9,552,412), respectively. For the year ended April 30, 2026, our revenue was S$132,077 (US$103,694), and our net loss and accumulated deficit were S$6,157,779 (US$4,834,474) and S$18,324,909 (US$14,386,886). Business operations in Singapore contributed approximately 86.0% of our Group’s revenue for the year ended April 30, 2026. We believe these results reflect the initial impact of our efforts to broaden our customer base, reduce customer concentration and improve operational efficiency.
In addition, service revenue increased as a result of maintenance-based contracts for our customers. As we grow our product and software range, we expect that service revenue will continue to contribute a greater percentage of our revenue going forward.
Competitive Strengths
| ● | We have strong and stable relationships with our suppliers and customers. |
| ● | We have an experienced management team. |
| ● | We have integrated our software solutions within our product portfolio. |
| ● | We provide turn-key solutions. |
| ● | We provide reliable after-sales support. |
Business Strategies
We intend to strengthen our market position in the microscopy equipment industry by implementing the following business strategies and plans.
| ● | Expand business and operations through joint ventures and/or strategic alliances in the Southeast Asia Market. |
| ● | Strengthening our global presence via marketing. |
| ● | Widening our product range. |
| 3 |
Brief Introduction to Our Products
Below are our products which are presently on sale:
Our Optonano series offers super-resolution imaging down to 137nm and high-speed data acquisition. It enables users to view live and still images with ease, and is capable of high-magnification with its 100x lens and super-resolution (“Optonano Lens”) applications to construct high-quality image of larger sample areas. Additionally, its in-built auto focus is deployed on the camera setting to allow users to achieve optimized imaging automatically on target observation.
Our PT-Industrial (“PT-I”) series is used for material study, failure analysis, simple measuring, quality control, inspection and manufacturing. It possesses several observation methods, including images produced by uniformly illuminating the sample so as to allow the specimen to appear as a dark image against a brightly lit background (“Brightfield”), images that are produced by using scattered light outside of the lens to observe the surface of an image against a dark background (“Darkfield”), the utilization of polarized lights between filters to enhance the color demonstration of images for better identification of the image’s material (“Polarization”), the conversion of phase shifts through varying brightness for observing transparent samples through delaying the different light wavelengths when it passes through the transparent sample (“Phase contrast”) and the usage of polarized light to convert phase delays into changes in intensity for viewing opaque samples ((“Differential Interference Contrast) (“DIC”)), providing high-resolution imaging and advanced observation techniques for different samples. Further, the hardware can also be customized to address the needs of the customers. This allows us to develop solutions for niche markets, where existing solutions either do not address, and/or too expensive because they are built for a broader generic market. Our solutions are also able to be integrated into existing systems to allow for more seamless operational efficiency for our customers.
Our PT-Metrology (“PT-M”) series offers quick dimensional measurements with a single key operation. The Double Telecentric Optical Lens facilitates accurate measurement across the entire depth of field without focusing multiple times. Additionally, its motorized Z-Axis and XY Stage provides a Z-Axis Travel Range up to 200mm and image sensor up to 20MP CMOS, with a field of view up to 500mm x 400mm, and a loading capacity up to 20kg. Lastly, the one key measurement function via an intuitive interface allows any operator to take accurate measurements with ease.
Our PT-Biology (“PT-B”) series is developed to address specialized images needed in the biomedical sector, especially in pathology. It is equipped with infinity plan achromatic objectives and wide field eyepieces, with Brightfield, Phase Contrast and Polarization observation methods. Its built-in field diaphragm, adjustable brightness, high image contrast, and 40-1600x Magnification Range is specifically designed for use in the biomedical industry which required transmission light to observe the sample.
Our PT-Stereo (“PT-S”) series is our specialized system internally developed for quality assurance and control application. The series is a stereo microscope designed to provide clear magnified stereoscopic images that amplify solid or thick samples. With a long working distance of 110mm and wide zoom range from 0.7x - 6.3x, this series offers real-time image observation, while its adjustable and customizable bottom and top light-emitting diode (“LED”) light sources provides better imaging. This is a 3D microscopy that is commonly used for QA/QC inspections.
Our PT-Zoom (“PT-Z”) series provides three-dimensional magnified view of samples to enhance visualization for our users. The series offers motorized 360° 3D real-time image observation, allowing the sample to be observed in all directions, while the long working distance facilitates a large field of view, providing high-definition imaging quality using adjustable front and side LED light sources. Additionally, its adjustable rotation speed and continuous zoom allows for observation at multiple angles.
Functionality Testing, Inspection of Equipment and Quality Control
Our company has established a quality control and assurance system for the manufacture of our microscopy equipment. This quality inspection has resulted in the company achieving ISO 9001/14001/45001 certification on July 20, 2023. The exhaustive list for our quality control and assurance system includes but is not limited to:
| (a) | Selection of components from third party suppliers. All of our key components are from reputable companies with at least 10 years of track record in the market. | |
| (b) | Quality checks on incoming components from third party suppliers. For example, we build in-house inspection tools to verify critical incoming components’ quality. | |
| (c) | Post-manufacturing testing and inspection. For example, all outgoing equipment (depending on the respective model) will need to undergo a series of quality inspections through live sample imaging, accuracy check on the tolerance using master gauges, repeatability test, as well as functional test. Upon successfully passing the test, a certification number will be attached to the equipment. Prior to shipping, an equipment check list will be processed so that all parts and components are in place. |
| 4 |
Property, Plants and Equipment
A description of the Company’s leased properties is below:
Real Property
A description of the Company’s leased real properties are as follows:
| Location | Usage | Lease Period | Rent (per month) | Approximate area (sq m) | ||||||||
| The Curie Singapore Science Park Unit #02-01, Singapore 118258 | Office | December 15, 2025 to December 14, 2028 | S$ | 3,580.89 | 92.41 | |||||||
| 55 Ayer Rajah Crescent #05-05, Singapore 139949 | Design and Assembly | February 1, 2026 to January 31, 2029 | S$ | 2,131.45 | 90.70 | |||||||
Inventory
For our microscopy equipment sales, we maintain an inventory of individual components of the products, as well as the final assembled products which are in demand with our customers and hence easier to sell.
As of April 30, 2026, and April 30, 2025, we had inventories of S$543,712 (approximately US$426,868) including allowance for slow moving of S$2,597 (approximately US$2,039) and S$310,007 (approximately US$243,386), respectively.
Intellectual Property
Our Group’s intellectual property rights are important to its business. As of the date of this prospectus, the Group is presently in the process of registering one trademark in respect of its logo.
As of the date of this prospectus, the Group has registered the following domain name:
| Domain Name | Registered Owner | Registration Date | Expiry Date | |||
| www.phaostech.com | Phaos Technology Pte. Ltd. | August 12, 2023 | August 12, 2028 |
We were not involved in any proceedings with regard to, and we have not received notice of any claims of infringement of, any intellectual property rights that may be threatened or pending, in which we may be involved either as a claimant or respondent.
Corporate Information
Phaos Technology Cayman was incorporated in the Cayman Islands on March 7, 2024 for the purposes of listing our Class A Ordinary Shares. Our registered office in the Cayman Islands is at 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands. Our principal executive office is at 55 Ayer Rajah Crescent #05-05 Singapore 139949. Our telephone number at this location is +65 6224 6320. Our principal website address is www.phaostech.com. The information contained on our website does not form part of this prospectus. Our agent for service of process in the United States is Cogency Global Inc., 122 E. 42nd Street, 18th Floor, New York, New York 10168.
| 5 |
Corporate Structure
The chart below sets out our corporate structure as of the date of this prospectus.
Our Company was incorporated in the Cayman Islands on March 7, 2024 under the Companies Act as an exempted company with limited liability for the purposes of listing our Class A Ordinary Shares. Our authorized share capital is US$10,000,000,000 divided into 6,333,333,333,333 Class A Ordinary Shares and 333,333,333,334 Class B Ordinary Shares, par value US$0.0015 per share.
Our historical operations are that of PTPL, our operating subsidiary, which was incorporated in Singapore as a private company limited by shares on February 22, 2017. PTPL has been carrying on business since February 22, 2017 and is engaged in the sale and development of microscopy equipment and its related software.
Share Swap Agreements
On November 29, 2024, the Company proceeded with an internal reorganization whereby PTPL became our indirect wholly-owned subsidiary through a share swap. Subject to completion of the restructuring, both the ordinary and preferential shares of PTPL were swapped on a 1:125 basis to Phaos Technology Holdings (BVI) Limited. Subsequently, the shares of Phaos Technology Holdings (BVI) Limited were swapped 1:1 to Phaos Technology Holdings (Cayman) Limited, where the holders of the ordinary shares of PTPL eventually being swapped to Class A Ordinary Shares, and the holders of preferential shares of PTPL being swapped to Class B Ordinary Shares.
| 6 |
The material terms of the Share Swap Agreements are as follows:
| 1. | Sale and Purchase of Sale Shares: Vendors will sell and transfer the Sale Shares to the Purchaser (PTPL) free of encumbrances. Purchaser will buy and accept the Sale Shares from the Vendors under the same conditions. Purchaser is not obligated to complete the purchase unless all Sale Shares are transferred simultaneously. | |
| 2. | Consideration: The Purchase Consideration is determined on a willing buyer-willing seller basis. | |
| 3. | Vendors’ Obligations Pending Completion: Vendors are prohibited from dealing, transferring, or encumbering the Sale Shares after this Agreement is executed, unless explicitly permitted. | |
| 4. | Completion: Upon completion, Purchaser is to allot and issue Consideration Shares to Vendors and deliver signed share transfer forms, board resolutions, and an updated register of members. Vendor is to deliver signed share transfer forms, share certificates, and board approvals for the transfer, and provide relevant documents and approvals for share transfers to be updated. Upon fulfilment of obligations, legal and beneficial ownership of Sale Shares transfers to the Purchaser, with the consideration Shares issued ranking equally with existing issued shares. | |
| 5. | Warranties: Vendors jointly and severally warrant the truth and accuracy of all information provided as of the Agreement date and the Completion Date, with warranties deemed repeated during this period. | |
| 6. | Termination: If a Party breaches the Agreement and fails to remedy the breach within 14 days after notice, the aggrieved Party may exercise all legal or equitable rights and remedies. |
Recent Developments
On December 31, 2025, Mr. Andrew Yeo Eng Sian, an executive director and chief executive officer of the company resigned his position as chief executive officer and director of the Board, effective on December 31, 2025. Mr. Andrew Yeo Eng Sian’s decision was made solely for personal reasons and not due to any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, or practices. As of the date of this prospectus, it is the Company’s intention to maintain an advisory relationship with Mr. Andrew Yeo Eng Sian on terms to be determined upon entry into such advisory agreement.
To fill the vacancy created by Mr. Andrew Yeo Eng Sian’s resignation until the Company’s next annual general meeting called for the election of directors, the Board appointed Gan Hong Loon to serve as an interim chief executive officer, effective on December 31, 2025.
On December 31, 2025, Mr. Tay Beng Boon, an executive director and chief operating officer of the Company notified the Board of his decision to resign his position as executive officer and director of the Board, effective on December 31, 2025. Mr. Tay Beng Boon’s decision was made solely for personal reasons and not due to any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, or practices. As of the date of this prospectus, Mr. Tay Beng Boon has been appointed as managing director of Phaos Technology Pte. Ltd., a Singapore subsidiary of the Company.
On March 30, 2026, the Company adopted the Phaos Technology Holdings (Cayman) Limited 2026 equity incentive plan (the “2026 Equity Incentive Plan”) to motivate, attract and retain directors, consultants or key employees to exert their best efforts on behalf of the Company and link their personal interests to those of the Company’s shareholders. The 2026 Plan has a maximum number of 2,741,350 Class A ordinary shares, par value $0.0001 per share, of the Company available for issuance pursuant to all awards under the 2026 Equity Incentive Plan.
Effective on March 31, 2026, the Company dismissed its independent registered auditor, Kreit & Chiu CPA LLP (“Kreit & Chiu”).
On March 31, 2026, the audit committee (the “Audit Committee”) of the board (the “Board”) of directors and the Board approved and ratified the appointment of AssentSure PAC (“AssentSure”) as the Company’s new independent registered public accounting firm to audit the Company’s financial statements, effective March 31, 2026.
On August 12, 2026, we issued a revised notice and proxy statement stating that our extraordinary general meeting of shareholders, originally scheduled for August 18, 2026, would be reconvened and held virtually on August 31, 2026. The extraordinary general meeting was held on August 31, 2026, and our shareholders approved each of the proposals described below.
Increase in authorized share capital. Shareholders approved an increase in our authorized share capital from US$100,000, divided into 950,000,000 Class A ordinary shares and 50,000,000 Class B ordinary shares, each with a par value of US$0.0001, to US$10.0 billion, divided into 95,000,000,000,000 Class A ordinary shares and 5,000,000,000,000 Class B ordinary shares, each with a par value of US$0.0001.
Share consolidation. Shareholders approved a consolidation of every 15 issued and unissued Class A ordinary shares into one Class A ordinary share and every 15 issued and unissued Class B ordinary shares into one Class B ordinary share. Following the share consolidation, each Class A and Class B ordinary share would have a par value of US$0.0015, and our authorized share capital would consist of 6,333,333,333,333 Class A ordinary shares and 333,333,333,334 Class B ordinary shares.
The share consolidation is intended to increase the per-share trading price of our Class A ordinary shares and enhance our ability to comply with the continued listing standards of the NYSE American, including its low selling-price requirements. There can be no assurance, however, that the share consolidation will produce a proportionate or sustained increase in the market price of our Class A ordinary shares or enable us to maintain our NYSE American listing.
| 7 |
The share consolidation proportionately reduced the number of issued and outstanding Class A and Class B ordinary shares. Shareholders’ proportionate ownership interests generally remained unchanged, except for adjustments resulting from the treatment of fractional shares. No fractional shares were issued; instead, fractional entitlements were rounded up to the nearest whole share. Corresponding adjustments were also made to the number of shares issuable, and the applicable exercise or conversion prices, under outstanding options, warrants and convertible or exchangeable securities.
Amendment and restatement of organizational documents. Shareholders approved the adoption of a third amended and restated memorandum and articles of association that would:
| ● | permit holders of Class B ordinary shares to convert those shares into Class A ordinary shares at the holder’s option; | |
| ● | designate the courts of the Cayman Islands as the exclusive forum for certain derivative, fiduciary-duty, Cayman law and internal corporate claims, subject to exceptions for direct claims under the Securities Act or Exchange Act and claims subject to the exclusive jurisdiction of the U.S. federal courts; | |
| ● | permit an ordinary shareholder resolution to be passed in writing by shareholders representing a majority of the voting rights entitled to vote on the resolution, replacing the existing unanimous written-consent requirement; and | |
| ● | reflect the approved increase in authorized share capital and the approved share consolidation. |
Issuance of Class B ordinary shares to the Chief Executive Officer. Shareholders approved the allotment and issuance of 2,900,000 pre-reverse stock split Class B ordinary shares to Hong Loon Gan, our Chief Executive Officer and a director, as compensation for services rendered in connection with the successful completion of our initial public offering. The shares would carry an aggregate of 58,000,000 votes pre-reverse stock split and would increase Mr. Gan’s voting power. The audit committee and the board of directors reviewed and approved the issuance as a related-party transaction in accordance with the Company’s related-party transaction policies and applicable NYSE American requirements.
Shareholders also authorized the directors and relevant service providers to take the administrative actions and make the Cayman Islands filings necessary to implement the approved proposals.
Share Consolidation
Pursuant to the shareholder approval obtained at the extraordinary general meeting held on August 31, 2026, on September 14, 2026, our board of directors approved a share consolidation of all of our authorized and issued Class A Ordinary Shares and Class B Ordinary Shares at a ratio of one-for-fifteen (1-for-15). No fractional shares were issued in connection with the share consolidation, and fractional entitlements were rounded up to the nearest whole share.
Set out below are our basic and diluted net loss per Class A Ordinary Share and the weighted average number of Class A Ordinary Shares outstanding for the fiscal years ended April 30, 2024, 2025 and 2026, both before, and after the share consolidation. Amounts presented on a post-share consolidation basis have been retrospectively adjusted to give effect to the share consolidation for all periods presented. Weighted-average share counts are rounded to the nearest whole share for presentation only, and loss-per-share amounts are rounded to two decimal places. Loss per share is calculated using the unrounded split-adjusted weighted-average share denominators.
For the fiscal year ended April 30, 2024, our net loss was S$2,359,844 (US$1,852,714). Our basic and diluted net loss per share was S$0.26 (US$0.20) before the share consolidation, and S$3.90 (US$3.06) after the share consolidation. Our weighted average number of ordinary shares outstanding was 9,075,989 before the share consolidation, and 605,066 after the share consolidation. The U.S.-dollar amounts in this paragraph only have been calculated solely for convenience at US$0.7851 per S$1.00. Loss per share was calculated using the unrounded translated loss amount and the unrounded weighted-average share denominator.
For the fiscal year ended April 30, 2025, our net loss was S$5,137,064 (US$4,033,109). Our basic and diluted net loss per share was S$0.49 (US$0.38) before the share consolidation, and S$7.31 (US$5.74) after the share consolidation. Our weighted average number of ordinary shares outstanding was 10,537,688 before the share consolidation, and 702,513 after the share consolidation.
For the fiscal year ended April 30, 2026, our net loss was S$6,157,779 (US$4,834,474). Our basic and diluted net loss per share was S$0.49 (US$0.38) before the share consolidation, and S$7.32 (US$5.75) after the share consolidation. Our weighted average number of ordinary shares outstanding was 12,610,917 before the share consolidation, and 840,728 after the share consolidation.
Our audited financial statements for the fiscal year ended April 30, 2026, which are incorporated by reference into this prospectus, were issued before the share consolidation took effect. As a result, the share and per share amounts in those financial statements do not reflect the share consolidation. Unless we say otherwise, all other share and per share amounts in this prospectus reflect the share consolidation.
Implications of Our Being an Emerging Growth Company
As a company with less than US$1.235 billion in revenue during our last fiscal year, we qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include:
| ● | being permitted to provide only two financial years of selected financial information (rather than five years) and only two years of audited financial statements (rather than three years), in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure; and | |
| ● | an exemption from compliance with the auditor attestation requirement of the Sarbanes-Oxley Act, on the effectiveness of our internal control over financial reporting. |
| 8 |
We may take advantage of these reporting exemptions until we are no longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last day of the fiscal year in which the fifth anniversary of the completion of this offering occurs, (2) the last day of the fiscal year in which we have total annual gross revenue of at least US$1.235 billion, (3) the date on which we are deemed to be a “large accelerated filer” under the Exchange Act, which means the market value of our Class A Ordinary Shares that are held by non-affiliates exceeds US$700.0 million as of the prior April 30, and (4) the date on which we have issued more than US$1.0 billion in non-convertible debt during the prior three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We have included two years of selected financial data in this prospectus in reliance on the first exemption described above. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock.
Implications of Our Being a Foreign Private Issuer
We are subject to the Exchange Act as a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including:
| ● | the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; | |
| ● | the sections of the Exchange Act regarding liability for insiders who profit from trades made in a short period of time; and | |
| ● | the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or the SEC, of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. |
Both foreign private issuers and emerging growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an emerging growth company but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither emerging growth companies nor foreign private issuers.
In addition, as a company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the corporate governance listing requirements of the NYSE American. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing requirements of the NYSE American. Following this offering, we will rely on home country practice to be exempted from certain of the corporate governance requirements of the NYSE American, namely (i) a majority of the Directors on our Board are not required to be independent Directors; (ii) there will not be a necessity to have regularly scheduled executive sessions with independent Directors; and (iii) there will be no requirement for the Company to obtain shareholder approval prior to an issuance of securities in connection with (a) the acquisition of stock or assets of another company; (b) equity-based compensation of officers, directors, employees or consultants; (c) a change of control; and (d) transactions other than public offerings.
Risk Factor Summary
Below please find a summary of the principal risks and uncertainties related to this Resale, organized under relevant headings. These risks are discussed more fully under “Item 3. Key Information — 3.D. Risk Factors” in our annual report on Form 20-F for the fiscal year ended April 30, 2026.
Risks Related to the Resale Offering
| ● | It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the Selling Shareholder, or the actual gross proceeds resulting from those sales. |
| ● | Our ability to sell the maximum number of shares permitted to be sold under the Purchase Agreement to the Selling Shareholder may be limited by its terms and conditions. |
| ● | The sale and issuance of Class A Ordinary Shares to the Selling Shareholder may cause dilution to our existing shareholders, and the sale of the Class A Ordinary Shares acquired by the Selling Shareholder, or the perception that such sales may occur, could cause the price of our Class A Ordinary Shares to fall. |
| ● | Investors who buy shares at different times will likely pay different prices. |
| ● | Our management team will have broad discretion over the use of the net proceeds from our sale of Class A Ordinary Shares to the Selling Shareholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully. |
| 9 |
THE OFFERING
| Class A Ordinary Shares offered by the Selling Shareholder: | Up to 406,808 Class A Ordinary Shares, consisting of: | ||
| ● | up to 365,486 Class A Ordinary Shares we may elect to issue and sell to the Selling Shareholder under the Purchase Agreement; and | ||
| ● | 41,322 Commitment Shares issuable under the Purchase Agreement. | ||
| Selling Shareholder | High West Partners LLC | ||
| Class A Ordinary Shares issued and outstanding prior to this Offering | 1,096,458 Class A Ordinary Shares as of October 20, 2026 | ||
| Class A Ordinary Shares issued and outstanding after giving effect to the issuance of the shares registered hereunder | Up to 1,503,266 Class A Ordinary Shares, assuming issuance of all Purchase Shares and Commitment Shares registered hereby | ||
| Plan of Distribution: | The Selling Shareholder, and any of their respective pledgees, and successors in interest, may offer or sell the Purchase Shares and Commitment Shares from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The Selling Shareholder may also resell the Purchase Shares and Commitment Shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions. See “Plan of Distribution” of this prospectus for additional information on the methods of sale that may be used by the Selling Shareholder. | ||
| Use of Proceeds: | We will not receive any proceeds from the sales of Class A Ordinary Shares by the Selling Shareholder. We have not received, and will not receive, any cash proceeds from the issuance of the Commitment Shares. We may receive up to $10,000,000 in aggregate gross proceeds under the Purchase Agreement from sales of Class A Ordinary Shares that we may elect to make to the Selling Shareholder pursuant to the Purchase Agreement, if any, from time to time in our sole discretion, from and after the Commencement Date. See “Use of Proceeds” starting from page 14 of this prospectus. | ||
| Risk Factors: | Investing in our Class A Ordinary Shares involves a high degree of risk. As an investor, you should be able to bear a complete loss of your investment. You should carefully consider the information set forth in the “Risk Factors” section beginning on page 11 of this prospectus, the “Risk Factors” section in our 2026 Annual Report, and in the “Risk Factors” section in any applicable prospectus supplement and any document incorporated by reference herein, before deciding to invest in our Class A Ordinary Shares. | ||
| Trading market and symbol: | Our Class A Ordinary Shares are listed on the NYSE American under the symbol “POAS”. | ||
| Beneficial Ownership Limitation: | The Purchase Agreement prohibits issuances that would cause the Selling Shareholder and the other attribution parties specified therein to beneficially own more than 4.99% of our outstanding Class A ordinary shares immediately after issuance. The Selling Shareholder may increase or decrease that percentage to a percentage not exceeding 9.99%; an increase takes effect on the 61st day after notice to us. | ||
| 10 |
RISK FACTORS
You should carefully consider the risks incorporated by reference in this prospectus before making an investment decision. You should also consider the matters described below and in “Risk Factors” in “Item 3. Key Information—D. Risk factors” in our annual report on Form 20-F for the fiscal year ended April 30, 2026, and all of the information included or incorporated by reference in this prospectus before deciding whether to purchase our Class A Ordinary Shares. Our business, financial condition and results of operations could be materially and adversely affected by any of these risks or uncertainties. In that case, the trading price of our Class A Ordinary Shares could decline, and you may lose all or part of your investment. The risks also include forward-looking statements and our actual results may differ substantially from those discussed in these forward-looking statements. See “Special Note Regarding Forward-Looking Statements.”
We may not be successful in preventing the material adverse effects that any of the following risks and uncertainties may cause. These potential risks and uncertainties may not be a complete list of the risks and uncertainties facing us. There may be additional risks and uncertainties that we are presently unaware of, or presently consider immaterial, that may become material in the future and have a material adverse effect on us. You could lose all or a significant portion of your investment due to any of these risks and uncertainties.
Risks Related to the Resale Offering
It is not possible to predict the actual number of shares we will sell under the Purchase Agreement to the Selling Shareholder, or the actual gross proceeds resulting from those sales.
On September 28, 2026, we entered into the Purchase Agreement with the Selling Shareholder, pursuant to which, upon the terms and subject to the satisfaction of the conditions contained in the Purchase Agreement, the Selling Shareholder has committed to purchase, at our direction in our sole discretion, up to an aggregate of $10,000,000 of Class A Ordinary Shares, subject to certain limitations set forth in the Purchase Agreement, from time to time during the term of the Purchase Agreement. Sales of Class A Ordinary Shares by the Company to the Selling Shareholder under the Purchase Agreement, if any, may occur, from time to time at our sole discretion, over the period commencing upon the Commencement, or the satisfaction of all conditions to the Selling Shareholder’s purchase obligations set forth in the Purchase Agreement, including that the registration statement we are required to file with the SEC pursuant to the Registration Rights Agreement, which is the registration statement of which this prospectus forms a part, is declared effective by the SEC, and ending upon the termination of the Purchase Agreement automatically in accordance with its terms or earlier under its terms.
We may ultimately decide to sell to the Selling Shareholder all, some or none of the shares that may be available for us to sell to the Selling Shareholder pursuant to the Purchase Agreement. Because the purchase price per share to be paid by the Selling Shareholder for Class A Ordinary Shares that we may elect to issue and sell to the Selling Shareholder under the Purchase Agreement, if any, will fluctuate based on the market prices of the Class A Ordinary Shares during the applicable period for each purchase made pursuant to the Purchase Agreement, if any, it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of shares that we will sell to the Selling Shareholder under the Purchase Agreement, the purchase price per share that the Selling Shareholder will pay for shares purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by the Selling Shareholder under the Purchase Agreement, if any.
| 11 |
Our ability to sell the maximum number of shares permitted to be sold under the Purchase Agreement to the Selling Shareholder may be limited by its terms and conditions.
Our ability to sell Purchase Shares to the Selling Shareholder under the Purchase Agreement is subject to the satisfaction of the conditions and compliance with the purchase limitations set forth therein, including the applicable purchase amount and trading volume limitations for Single Day Purchases and VWAP Purchases. Accordingly, depending on the market prices and trading volumes of our Class A Ordinary Shares and our ability to satisfy the applicable conditions, we may be unable to sell all of the Purchase Shares available under the Purchase Agreement or raise the full amount of proceeds contemplated thereby.
Moreover, we may not issue or sell any Class A Ordinary Shares to the Selling Shareholder under the Purchase Agreement which, when aggregated with all other Class A Ordinary Shares then beneficially owned by the Selling Shareholder and the other Attribution Parties specified in the Purchase Agreement (as calculated pursuant to Section 13(d) of the Exchange Act, and Rule 13d-3 promulgated thereunder), would result in the Selling Shareholder beneficially owning more than the Beneficial Ownership Limitation. These requirements and limitations could materially adversely affect the ability of the Company to generate gross proceeds provided for under the Purchase Agreement.
Our ability to obtain financing under the Purchase Agreement depends on satisfaction of its conditions and is subject to its purchase limitations. Accordingly, we may not be able to raise sufficient proceeds under the Purchase Agreement to meet our liquidity needs. If these proceeds are insufficient, we may need to obtain additional financing, which may not be available on acceptable terms or at all. Failure to obtain sufficient financing could adversely affect our ability to fund our operations and continue as a going concern.
The sale and issuance of Class A Ordinary Shares to the Selling Shareholder may cause dilution to our existing shareholders, and the sale of the Class A Ordinary Shares acquired by the Selling Shareholder, or the perception that such sales may occur, could cause the price of our Class A Ordinary Shares to fall.
The purchase price for the Class A Ordinary Shares that we may sell to the Selling Shareholder under the Purchase Agreement will fluctuate based on the price of our Class A Ordinary Shares. Depending on market liquidity at the time, sales of such shares may cause the trading price of our Class A Ordinary Shares to fall.
If and when we elect to issue and sell Class A Ordinary Shares to the Selling Shareholder pursuant to the Purchase Agreement and after the Selling Shareholder has acquired such shares, the Selling Shareholder may also resell all, some, or none of the shares at any time or from time to time in its discretion and at different prices. Therefore, our issuance of the Commitment Shares and any Purchase Shares to the Selling Shareholder could result in substantial dilution to the interests of existing holders of our Class A Ordinary Shares. Resales of those shares by the Selling Shareholder, or the perception that such resales may occur, could adversely affect the market price of our Class A Ordinary Shares.
Investors who buy shares at different times will likely pay different prices.
Pursuant to the Purchase Agreement, we will have discretion, subject to market demand and certain limitations set forth in the Purchase Agreement, to sell Class A Ordinary Shares to the Selling Shareholder at varying times, prices, and numbers. The Selling Shareholder may resell all, some or none of the Commitment Shares at any time or from time to time in its discretion and at different prices. If and when we elect to issue and sell shares to the Selling Shareholder pursuant to the Purchase Agreement and after the Selling Shareholder has acquired such shares, the Selling Shareholder may also resell all, some or none of the shares at any time or from time to time in its discretion and at different prices. As a result, investors who purchase Class A Ordinary Shares from the Selling Shareholder in this offering at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases, substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from the Selling Shareholder in this offering as a result of future sales made by us to the Selling Shareholder at prices lower than the prices such investors paid for their shares in this offering.
| 12 |
Our management team will have broad discretion over the use of the net proceeds from our sale of Class A Ordinary Shares to the Selling Shareholder, if any, and you may not agree with how we use the proceeds and the proceeds may not be invested successfully.
Our management team will have broad discretion as to the use of the net proceeds from our sale and issuance of Class A Ordinary Shares to the Selling Shareholder, if any, and we could use such proceeds for purposes other than those contemplated at the time of commencement of this offering. Accordingly, investors will be relying on the judgment of our management team with regard to the use of those net proceeds, and investors will not have the opportunity, as part of their investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management team to use such funds effectively could have a material adverse effect on our business, financial condition, operating results, and cash flows.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains forward-looking statements that relate to our current expectations and views of future events. These forward-looking statements are contained principally in the sections entitled “Prospectus Summary,” “Risk Factors,” “Use of Proceeds,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and “Business.” These statements relate to events that involve known and unknown risks, uncertainties, and other factors, including those listed under “Risk Factors,” which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In some cases, these forward-looking statements can be identified by words or phrases such as “believe,” “plan,” “expect,” “intend,” “should,” “seek,” “estimate,” “will,” “aim” and “anticipate,” or other similar expressions, but these are not the exclusive means of identifying such statements. All statements other than statements of historical facts included in this document, including those regarding future financial position and results, business strategy, plans and objectives of management for future operations (including development plans and dividends) and statements on future industry growth are forward-looking statements. In addition, we and our representatives may from time to time make other oral or written statements which are forward-looking statements, including in our periodic reports that we are required to file with the SEC, other information sent to our shareholders and other written materials.
These forward-looking statements are subject to risks, uncertainties, and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risk factors set forth in “Risk Factors” and the following:
| ● | our business and operating strategies and our various measures to implement such strategies; |
| ● | our operations and business prospects, including development and capital expenditure plans for our existing business; |
| ● | changes in policies, legislation, regulations or practices in the industry and those countries or territories in which we operate that may affect our business operations; |
| ● | our financial condition, results of operations and dividend policy; |
| ● | changes in political and economic conditions and competition in the area in which we operate, including a downturn in the general economy; |
| ● | the regulatory environment and industry outlook in general; |
| ● | future developments in the supply of microscopy equipment market and actions of our competitors; |
| 13 |
| ● | catastrophic losses from man-made or natural disasters, such as fires, floods, windstorms, earthquakes, diseases, epidemics, other adverse weather conditions or natural disasters, war, international or domestic terrorism, civil disturbances and other political or social occurrences; |
| ● | the loss of key personnel and the inability to replace such personnel on a timely basis or on terms acceptable to us; |
| ● | the overall economic environment and general market and economic conditions in the jurisdictions in which we operate; |
| ● | our ability to execute our strategies; |
| ● | changes in the need for capital and the availability of financing and capital to fund those needs; |
| ● | our ability to anticipate and respond to changes in the markets in which we operate, and in client demands, trends and preferences; |
| ● | exchange rate fluctuations, including fluctuations in the exchange rates of currencies that are used in our business; |
| ● | changes in interest rates or rates of inflation; and |
| ● | legal, regulatory and other proceedings arising out of our operations. |
The forward-looking statements made in this prospectus relate only to events or information as of the date on which the statements are made in this prospectus. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement, of which this prospectus is a part, completely and with the understanding that our actual future results or performance may be materially different from what we expect.
This prospectus contains certain data and information that we obtained from various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. The markets for the supply of microscopy equipment may not grow at the rate projected by such market data, or at all. Failure of this industry to grow at the projected rate may have a material and adverse effect on our business and the market price of our Class A Ordinary Shares. Furthermore, if any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements.
USE OF PROCEEDS
We will not receive any proceeds from sales of Class A Ordinary Shares by the Selling Shareholder. We will not receive any cash proceeds from the issuance of the Commitment Shares. We may receive up to US$10,000,000 in aggregate gross proceeds from sales of Purchase Shares that we may, in our sole discretion, elect to make to the Selling Shareholder pursuant to the Purchase Agreement from and after the Commencement Date, subject to the terms and conditions thereof. We will use the net proceeds from any such sales for general working capital or other corporate purposes at our sole discretion. See “High West Partners LLC Committed Equity Financing” for more information.
DIVIDEND POLICY
While we currently have no plans to distribute dividends, in the event we consider distributing a dividend in the future, our Board shall take into account, among other things, the following factors when deciding whether to propose a dividend and in determining the dividend amount: (a) operating and financial results; (b) cash flow situation; (c) business conditions and strategies; (d) future operations and earnings ; (e) taxation considerations; (f) interim dividend paid, if any; (g) capital requirement and expenditure plans; (h) interests of shareholders; (i) statutory and regulatory restrictions; (j) any restrictions on payment of dividends; and (k) any other factors that our Board may consider relevant. The payment of dividends, in certain circumstances is also subject to the approval of our Shareholders, the Companies Act and our Memorandum and Articles of Association as well as any other applicable laws. Currently, we do not have any predetermined dividend distribution ratio. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of Directors. Under the Companies Act, a Cayman Islands company may pay a dividend out of either profit or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business.
Even if our Board decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the Board may deem relevant. In addition, we are a holding company and depend on the receipt of dividends and other distributions from our subsidiaries to pay dividends on our Class A Ordinary Shares.
There are no foreign exchange controls or foreign exchange regulations under current applicable laws of the various places of incorporation of our significant subsidiaries that would affect the payment or remittance of dividends.
| 14 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
For our management’s discussion and analysis of financial condition and results of operations for the fiscal years ended April 30, 2025 and 2026, please see “Item 5. Operating and Financial Review and Prospects” in our annual report on Form 20-F for the fiscal year ended April 30, 2026, which is incorporated by reference into this prospectus.
PRINCIPAL SHAREHOLDERS
The following table sets forth information regarding the beneficial ownership of our share capital by:
| ● | each person, or group of affiliated persons, known by us to beneficially own more than 5% of our shares; |
| ● | each of our named Executive Officers; |
| ● | each of our Directors and Independent Directors; and |
| ● | all of our current Executive Officers, Directors and Independent Directors as a group. |
Applicable percentage ownership is based on 1,096,458 Class A Ordinary Shares and 1,008,354 Class B Ordinary Shares of our Company issued and outstanding as of October 20, 2026.
The information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of the SEC and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares the power to vote or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within sixty (60) days through the conversion or exercise of any convertible security, warrant, option or other right. More than one (1) person may be deemed to be a beneficial owner of the same securities. The percentage of beneficial ownership by any person as of a particular date is calculated by dividing the number of shares beneficially owned by such person, which includes the number of shares as to which such person has the right to acquire voting or investment power within sixty (60) days, by the sum of the number of shares outstanding as of such date, plus the number of shares as to which such person has the right to acquire voting or investment power within sixty (60) days. Consequently, the denominator used for calculating such percentage may be different for each beneficial owner. Except as otherwise indicated below and under applicable community property laws, we believe that the beneficial owners of our shares listed below have sole voting and investment power with respect to the shares shown.
| 15 |
Unless otherwise noted below, the address of each person listed on the table is 55 Ayer Rajah Crescent #05-05, Singapore 139949.
Amount of Beneficial Ownership of Class A Shares (1) |
Percentage Ownership of Class A Shares(2) | Amount of Beneficial Ownership of Class B Shares (1) | Percentage Ownership of Class B Shares(2) |
Combined Voting Power of Class A and Class B Shares(2) | ||||||||||||||||
| Directors, Independent Directors, and Executive Officers: | ||||||||||||||||||||
| Beh Hook Seng(3) | - | - | % | 530,918 | 52.65 | % | 49.94 | % | ||||||||||||
| Gan Hong Loon(4) | - | - | % | 213,843 | 17.80 | % | 17.02 | % | ||||||||||||
| Lionel Choong Khuat Leok(5) | - | - | % | - | - | % | - | % | ||||||||||||
| Wesley Yiu(5) | - | - | % | - | - | % | - | % | ||||||||||||
| Erik Cheong Wei Kiat(5) | - | - | % | - | - | % | - | % | ||||||||||||
| Liu Yi, Louis(5) | - | - | % | - | - | % | - | % | ||||||||||||
| Koh Boon Chiao(5) | - | - | % | - | - | % | - | % | ||||||||||||
| 5% or Greater Shareholders | ||||||||||||||||||||
| Tonghuai SG Enterprise Pte Ltd(6) | - | - | % | 317,317 | 31.47 | % | 29.85 | % | ||||||||||||
| Tonghuai SG2 Enterprise Pte Ltd(7) | - | - | % | 125,925 | 12.49 | % | 11.84 | % | ||||||||||||
| Singlight Technology Pte Ltd(8) | - | - | % | 256,684 | 25.46 | % | 24.14 | % | ||||||||||||
| Liew Ah Choy(9) | 68,611 | 6.26 | % | - | - | % | 0.32 | % | ||||||||||||
| (1) | Beneficial ownership includes shares over which a person exercises voting or investment power and shares that the person has the right to acquire within 60 days of October 20, 2026. Class A Ordinary Shares beneficially owned include Class A Ordinary Shares issuable upon conversion of Class B Ordinary Shares to the extent such conversion rights are exercisable within that period, as described in the applicable footnotes below. | |
| (2) | Ownership percentages are based on 1,096,458 Class A Ordinary Shares and 1,008,354 Class B Ordinary Shares issued and outstanding as of October 20, 2026, subject to the holder-specific adjustments described above. Each Class A Ordinary Share carries one vote and each Class B Ordinary Share carries twenty votes. Combined voting power reflects voting rights attached to outstanding shares and does not double-count Class A Ordinary Shares underlying unexercised Class B conversion rights. | |
| (3) | Beh Hook Seng holds 317,317 Class B ordinary shares through Tonghuai SG Enterprise Pte Ltd, and 213,601 Class B Ordinary Shares in his own name. Beh Hook Seng holds 100% of Tonghuai SG Enterprise Pte Ltd, has the power to direct the voting and disposition of the ordinary shares held by Tonghuai SG Enterprise Pte Ltd, and may be deemed the beneficial owner of all ordinary shares held by Tonghuai SG Enterprise Pte Ltd. | |
| (4) | Represents (i) 20,509 Class B Ordinary Shares which is beneficially owned, controlled and held by Gan Hong Loon and (ii) 193,334 Class B Ordinary Shares that Gan Hong Loon has a right to acquire, as approved by the extraordinary general meeting of shareholders held on August 31, 2026. | |
| (5) | Independent director. | |
| (6) | Represents 317,317 Class B Ordinary Shares held by Tonghuai SG Enterprise Pte Ltd, which is beneficially owned and controlled by Beh Hook Seng, and its current registered address is located at 20 Martin Road #10-01 Seng Kee Building Singapore 239070. | |
| (7) | Represents 125,925 Class B Ordinary Shares held by Tonghuai SG2 Enterprise Pte Ltd, which is beneficiary owned and controlled by Wong Teck Far and its current registered address is located at 20 Martin Road #10-01 Seng Kee Building Singapore 239070. | |
| (8) | Represents 256,684 Class B Ordinary Shares held by Singlight Technology Pte Ltd, which is beneficially owned and controlled by Hong Ming Hui, and its current registered address is located at 10 Ubi Crescent #04-19, Ubi Techpark, Singapore 408564. | |
| (9) | Represents 68,611 Class A Ordinary Shares beneficially owned and held by Liew Ah Choy. |
| 16 |
HIGH WEST Partners LLC Committed Equity Financing
On September 28, 2026, we entered into a securities purchase agreement (the “Purchase Agreement”) with High West Partners LLC, a California limited liability company (the “Investor”), pursuant to which we may, from time to time, sell to the Selling Shareholder the greater of (i) up to $10,000,000 of the Company’s Class A Ordinary Shares (the “Purchase Shares”), or (ii) if the Ordinary Shares are listed on any exchange operated by The Nasdaq Stock Market or the New York Stock Exchange (any, an “Exchange”), up to an amount of Ordinary Shares that constitutes the Exchange Cap (collectively, the “Commitment Amount”). The available amount under the Purchase Agreement is initially $10,000,000 and is reduced by the purchase amount each time the Selling Shareholder purchases shares. Separately, while our Class A Ordinary Shares are listed on an Exchange, the Exchange Cap operates as a limitation on the number of Class A Ordinary Shares issuable under the Purchase Agreement to no more than 19.99% of our Class A Ordinary Shares outstanding as of September 28, 2026, together with any floor price and shareholder approval requirements necessary to comply with the applicable Exchange rules, as described under “—Purchase Limitations” below. The Purchase Agreement refers to Class A Ordinary Shares with a par value of US$0.0001 per share, reflecting our share capital prior to the share consolidation approved by our shareholders on August 31, 2026; following the share consolidation, our Class A Ordinary Shares have a par value of US$0.0015 per share, and share numbers and prices under the Purchase Agreement are subject to appropriate adjustment. On the same date, we entered into a registration rights agreement with the Investor (the “Registration Rights Agreement”), pursuant to which we agreed to register the resale of the Purchase Shares and the Commitment Shares described below.
Sales of Class A Ordinary Shares pursuant to the Purchase Agreement, and the timing of any sales, will be solely at our option, and we will be under no obligation to sell any securities to the Selling Shareholder under the Purchase Agreement. In accordance with our obligations under the Registration Rights Agreement, we have filed the registration statement that includes this prospectus with the SEC to register under the Securities Act, the resale by the Selling Shareholder of up to 406,808 Class A Ordinary Shares, consisting of (i) up to 365,486 Class A Ordinary Shares that we may issue and sell to the Selling Shareholder, from time to time and (ii) 41,322 Commitment Shares that shall be fully earned as of the Commencement Date and issued upon the delivery of the first Purchase Notice. The number of Commitment Shares issuable under the Purchase Agreement will equal US$100,000 divided by the closing price of our Class A Ordinary Shares on the Commitment Shares Determination Date. Our right to sell Purchase Shares commences on the Commencement Date and continues until the first day of the month immediately following the 36-month anniversary of the Commencement Date (the “Maturity Date”), unless the Purchase Agreement is earlier terminated.
We do not have the right to commence any sales of our Class A Ordinary Shares to the Selling Shareholder under the Purchase Agreement until the Commencement Date, which is the date on which all of the conditions to the Company’s right to sell, and the Selling Shareholder’s purchase obligation set forth in the Purchase Agreement have been satisfied, including that the registration statement that includes this prospectus shall have been declared effective by the SEC and the final form of this prospectus shall have been filed with the SEC.
Single Day Purchases
From and after the Commencement Date, we may direct the Selling Shareholder to purchase Purchase Shares by delivering an irrevocable written purchase notice for a single day purchase (a “Single Day Purchase”). The purchase price per share for a Single Day Purchase is the average of the three lowest traded prices of our Class A ordinary shares on the applicable purchase date, subject to the adjustments specified in the Purchase Agreement.
| 17 |
The maximum number of shares that we may require the Selling Shareholder to purchase under a Single Day Purchase notice is the lesser of (i) 40% of the three-day average daily trading volume of our Class A ordinary shares and (ii) the Investment Limit divided by the highest closing sale price of our Class A ordinary shares over the five most recent trading days immediately preceding receipt of the notice. The “Investment Limit” is US$1,000,000 and may be increased by mutual consent. The Selling Shareholder may waive the Single Day Purchase share limit to permit the purchase of additional shares.
We must deliver the applicable Purchase Shares electronically to the Selling Shareholder’s designated brokerage account through the Depository Trust Company’s Deposit/Withdrawal at Custodian system (“DWAC”) alongside delivery of the purchase notice. For a notice to be deemed delivered on a particular business day, both the notice and the completed DWAC delivery must be received by 11:00 a.m., New York time, on that day. Otherwise, the notice is deemed delivered on the next business day, unless High West waives this requirement in writing.
The Selling Shareholder must pay for a Single Day Purchase by wire transfer of immediately available funds on the trading day following its receipt of the Purchase Shares through DWAC if the shares are received before 11:00 a.m., Eastern time, or on the second trading day following receipt if the shares are received after that time.
VWAP Purchases
The Purchase Agreement also provides for purchases based on the volume-weighted average price of our Class A ordinary shares (“VWAP Purchases”). Subject to the applicable conditions, we may direct the Selling Shareholder to purchase shares by delivering an irrevocable written VWAP purchase notice.
The purchase price per share for a VWAP Purchase is 97% of the lowest daily volume-weighted average price of our Class A ordinary shares during the three consecutive trading days beginning with the Selling Shareholder’s receipt of the applicable notice, subject to the adjustments specified in the Purchase Agreement. The maximum number of shares specified in a VWAP purchase notice may not exceed 200% of the average daily trading volume of our Class A ordinary shares for the five trading days preceding the Selling Shareholder’s receipt of the notice.
The notice and accompanying DWAC delivery requirements for VWAP Purchases use the same 11:00 a.m., New York time, cutoff described above. In addition, we may deliver a VWAP Purchase Notice only (i) on a VWAP Purchase Date on which we have also properly submitted a purchase notice providing for a purchase of a number of Purchase Shares less than the VWAP Purchase Share Maximum then in effect, and (ii) after we have delivered the applicable Purchase Shares as DWAC shares to the Selling Shareholder’s designated brokerage account. The Selling Shareholder must provide a written purchase confirmation within four trading days after the applicable VWAP purchase date and pay for the Purchase Shares on the fourth trading day following its receipt of those shares through DWAC.
Purchase Limitations
Unless the Selling Shareholder waives the limitation for a particular request, we may not submit more than one Single Day Purchase notice or more than one VWAP purchase notice on any single trading day.
We may not deliver purchase notices during the contractual period surrounding a post-effective amendment to the applicable registration statement or while our shares trade over the counter rather than on a registered national securities exchange, unless the Selling Shareholder waives the applicable restriction. We also may not deliver purchase notices while a Suspension Event, or an event that would become a Suspension Event after notice or the passage of time, has occurred and is continuing. Suspension Events include specified registration statement unavailability, trading suspensions, failures to deliver shares, material breaches, insolvency events and loss of DWAC eligibility, subject to the qualifications and cure periods in the Purchase Agreement.
The Purchase Agreement prohibits any issuance or sale reasonably expected to violate the Securities Act or the rules and regulations of the principal trading market for our Class A ordinary shares. If our shares are listed on an exchange operated by Nasdaq or the New York Stock Exchange, the parties have agreed, to the extent necessary to comply with the applicable exchange rules, to amend the Purchase Agreement to add a floor price (which the Purchase Agreement sets at US$0.10 per share, subject to adjustment for the share consolidation and other specified events) and any required shareholder approval requirements addressing an issuance limit of 19.99% of the outstanding Class A ordinary shares as of September 28, 2026 (the “Exchange Cap”).
| 18 |
In addition, we may not issue shares to the Selling Shareholder to the extent that, after giving effect to the issuance, the Selling Shareholder and the other attribution parties specified in the Purchase Agreement would beneficially own more than 4.99% of our outstanding Class A ordinary shares. The Selling Shareholder may, upon written notice to us, increase or decrease this limitation to a percentage not exceeding 9.99%, provided that any increase will not become effective until the 61st day after delivery of the notice.
Commitment Shares and Expenses
As consideration for the Selling Shareholder’s commitment under the Purchase Agreement, we have agreed to issue Class A ordinary shares equal to US$100,000 divided by the closing price of our Class A ordinary shares on the Commitment Shares Determination Date (the “Commitment Shares”). The Commitment Shares Determination Date is the earlier of (i) the business day immediately preceding effectiveness of the registration statement and (ii) the business day immediately preceding the Selling Shareholder’s delivery of a written request for issuance of the Commitment Shares. For avoidance of doubt, all of the Commitment Shares shall be fully earned as of the Commencement Date and issued upon the delivery of the first Purchase Notice. We will not receive cash proceeds from issuance of the Commitment Shares.
We have agreed to reimburse the Selling Shareholder for US$15,000 of its legal fees, which we may elect to satisfy by permitting the Selling Shareholder to withhold that amount from the first purchase payment. We will also pay the clearing costs associated with each Purchase Notice and any transfer agent fees incurred by the Selling Shareholder.
Registration Rights
Under the Registration Rights Agreement, we agreed to file a resale registration statement on Form F-1 within 30 calendar days after September 28, 2026, subject to the delay provisions in that agreement, and to use commercially reasonable efforts to obtain effectiveness at the earliest practicable date. We also agreed to use commercially reasonable efforts to maintain the registration statement’s effectiveness and availability until the Selling Shareholder has resold all securities covered thereby and no additional Class A ordinary shares remain issuable under the Purchase Agreement.
If the registered shares are insufficient to cover the registrable securities, we must, to the extent necessary and permissible, amend the registration statement or file an additional registration statement as soon as reasonably practicable and no later than 10 business days after the need arises, subject to applicable SEC limitations.
The Registration Rights Agreement permits us to delay effectiveness or suspend use of the prospectus in specified circumstances. Certain suspensions are subject to limits of 30 consecutive trading days or 90 trading days in any 365-day period, with exceptions for specified legal, regulatory, disclosure and other circumstances described in that agreement. We will bear the registration expenses allocated to us under the Registration Rights Agreement.
High West is an underwriter within the meaning of Section 2(a)(11) of the Securities Act in connection with its resales under this prospectus. See “Selling Shareholder” and “Plan of Distribution.”
Termination of the Purchase Agreement
We may terminate the Purchase Agreement at any time, for any reason or no reason, upon at least one trading day’s prior written notice to the Selling Shareholder. No termination fee, penalty, liquidated damages or other compensation is payable solely as a result of that termination. Upon delivery of a termination notice, we may not issue further purchase notices. Valid purchase notices delivered before the effective date of termination remain binding and must be completed and paid for in accordance with the Purchase Agreement. Termination does not affect accrued rights or obligations, and Commitment Shares already issued remain fully earned and non-refundable.
The Purchase Agreement also provides for termination upon a material breach by either party, subject to its terms, and automatic termination upon specified events, including maturity, completion of the contractual purchase commitment, certain insolvency events and the delisting of our Class A Ordinary Shares from the NYSE American (or any other New York Stock Exchange market that is then the principal market for our Class A Ordinary Shares).
No Short-Selling or Hedging by Selling Shareholder
The Selling Shareholder has agreed that from the date of the Purchase Agreement until its termination, neither it nor its agents, representatives or affiliates will, directly or indirectly, effect any short sale of our Class A Ordinary Shares or any hedging transaction that establishes a net short position in our Class A Ordinary Shares, or otherwise violate Regulation SHO under the Exchange Act.
Restrictions on Other Equity Line Transactions
During the term of the Purchase Agreement, we may not enter into another equity line transaction substantially similar to the Purchase Agreement without the Selling Shareholder’s prior written consent, which may not be unreasonably withheld, conditioned or delayed. Except for this restriction, we remain free to enter into, announce and complete other financing transactions, including public offerings, follow-on offerings, private placements, at-the-market offerings, debt or convertible financings, strategic investments, acquisition financings and issuances under equity incentive plans. For the avoidance of doubt, our follow-on public offering contemplated by the registration statement on Form F-1 initially filed with the SEC on May 18, 2026 shall be permitted.
| 19 |
SELLING SHAREHOLDER
This prospectus relates to the possible resale from time to time by High West Partners LLC (“High West” or “Selling Shareholder”) of any or all of the Class A Ordinary Shares that may be issued by us to High West under the Purchase Agreement. For additional information regarding the issuance of Class A Ordinary Shares covered by this prospectus, see “High West Partners LLC Committed Equity Financing”. We are registering the Class A Ordinary Shares pursuant to the provisions of the Registration Rights Agreement we entered into with High West on September 28, 2026, in order to permit the Selling Shareholder to offer the shares for resale from time to time. Except for the transactions contemplated by the Purchase Agreement and the Registration Rights Agreement, High West has not had any material relationship with us within the past three years.
The table below presents information regarding the Selling Shareholder and the Class A Ordinary Shares that it may offer from time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Shareholder and reflects holdings as of the date of this prospectus. The number of shares in the column “Maximum Number of Ordinary Shares to be Offered Pursuant to this Prospectus” represents all of the Class A Ordinary Shares that the Selling Shareholder may offer under this prospectus. The Selling Shareholder may sell some, all or none of its shares in this offering. We do not know how long the Selling Shareholder will hold the shares before selling them, and Other than the Purchase Agreement and the Registration Rights Agreement, we currently have no agreements, arrangements or understandings with the Selling Shareholder regarding the sale of any of the shares.
Beneficial ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act and includes ordinary shares with respect to which the Selling Shareholder has voting and investment power. The percentage of Class A Ordinary Shares beneficially owned by the Selling Shareholder prior to the offering shown in the table below is based on an aggregate of 1,096,458 of our Class A Ordinary Shares issued and outstanding as of October 20, 2026. Because the purchase prices of the Purchase Shares issuable under the Purchase Agreement are determined in accordance with the applicable Single Day Purchase or VWAP Purchase pricing provisions, the number of Purchase Shares that we actually sell to High West under the Purchase Agreement may be fewer than the number registered for resale under this prospectus. The table below assumes the issuance and sale of all shares offered by the Selling Shareholder pursuant to this prospectus.
| 20 |
| Name of Selling Shareholder | Number of Class A Ordinary Shares Owned Prior to Offering | Maximum Number of Class A Ordinary Shares to be Offered Pursuant to this Prospectus (3) | Number of Class A Ordinary Shares Owned After Offering | |||||||||||||||||
| Number(1) | Percent(2) | Number(4) | Percent(2) | |||||||||||||||||
High West Partners LLC (5) | 0 | 0 | % | 406,808 | 0 | 0 | % | |||||||||||||
| (1) | Represents the number of Class A Ordinary Shares beneficially owned by High West as of the date of this prospectus. This number excludes Purchase Shares that High West may be required to purchase under the Purchase Agreement, because any such purchases are at our discretion and subject to the satisfaction of the conditions set forth in the Purchase Agreement, including the registration statement of which this prospectus forms a part having been declared effective by the SEC and the prospectus being current and available for resales by High West. Single Day Purchases and VWAP Purchases are also subject to the applicable purchase limitations set forth in the Purchase Agreement. In addition, the Purchase Agreement prohibits us from issuing and selling any shares of our Class A Ordinary Shares to High West to the extent that, after giving effect to the issuance, High West and the other attribution parties specified therein would beneficially own more than 4.99% of our outstanding Class A Ordinary Shares. High West may increase or decrease this limitation to a percentage not exceeding 9.99%, provided that any increase will not become effective until the 61st day after delivery of written notice to us. |
| (2) | Applicable percentage ownership is based on 1,096,458 Class A Ordinary Shares issued and outstanding as of October 20, 2026. |
| (3) | Consists of up to 365,486 Purchase Shares that we may, in our sole discretion, elect to issue and sell to the Selling Shareholder from time to time under the Purchase Agreement, and 41,322 Commitment Shares issuable to the Selling Shareholder pursuant to the Purchase Agreement, registered for resale under this prospectus. The number of shares shown in this column does not give effect to the Beneficial Ownership Limitation under the Purchase Agreement. |
| (4) | Assuming all of the Class A Ordinary Shares being registered hereby will be resold. |
| (5) | High West Partners LLC is a California limited liability company. The principal business address of High West Partners LLC (“High West”) is 23371 Mulholland Drive, Suite 228, Woodland Hills, CA 91364. Dmitriy Slobodskiy Jr. and Jacob Carmi are the managing principals of High West. Therefore, each gentleman may be deemed to have sole voting control investment discretion over the securities beneficially held by High West. We have been advised that High West is not a member of the Financial Industry Regulatory Authority or an independent broker-dealer. The foregoing should not be construed in and of itself as an admission by Slobodskiy Jr. as to beneficial ownership of the securities beneficially owned by High West. |
| 21 |
DESCRIPTION OF SECURITIES WE ARE OFFERING
General
Our authorized share capital is US$10,000,000,000 divided into 6,333,333,333,333 Class A Ordinary Shares and 333,333,333,334 Class B Ordinary Shares, par value US$0.0015 per share. All of our issued Ordinary Shares are fully paid and non-assessable. Our Ordinary Shares are issued in registered book-entry form and are issued when registered in our register of members. Unless the board of directors determine otherwise, each holder of our Ordinary Shares will not receive a certificate in respect of such Ordinary Shares. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their Ordinary Shares.
As of October 20, 2026, there are 1,096,458 Class A Ordinary Shares and 1,008,354 Class B Ordinary Shares issued and outstanding.
Type of Securities
Each Ordinary Share has a par value of US$0.0015 per share. The number of Ordinary Shares that had been issued as of the last day of the financial year ended April 30, 2026 (prior to the share consolidation) is provided on the cover of the annual report on Form 20-F filed on August 31, 2026. Our Ordinary Shares are issued in registered form and are issued when registered in our register of members. We may not issue shares to bearer. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote for their shares.
Preemptive Rights
Our Ordinary Shares are not subject to any pre-emptive or similar rights under either Cayman Islands law or our Memorandum and Articles of Association.
Rights of Ordinary Shares
Ordinary Shares
The Company is authorised to issue 6,333,333,333,333 Class A Ordinary Shares and 333,333,333,334 Class B Ordinary Shares, par value US$0.0015 per share. Our Ordinary Shares are issued in registered form and are issued when registered in our register of members. We may not issue shares to a bearer. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their shares. Subject to the provisions of the Companies Act and our Articles regarding redemption and purchase of the shares, the Directors have general and unconditional authority to allot (with or without confirming rights of renunciation), grant options over or otherwise deal with any unissued shares to such persons, at such times and on such terms and conditions as they may decide. The Directors may deal with unissued shares either at a premium or at par, or with or without preferred, deferred or other special rights or restrictions, whether in regard to dividend, voting, return of capital or otherwise. No share may be issued at a discount except in accordance with the provisions of the Companies Act. The directors may refuse to accept any application for shares and may accept any application in whole or in part, for any reason or for no reason.
Dividends
Our Memorandum and Articles provide that dividends may be declared and paid out of the funds of our Company lawfully available therefor by the Directors and our shareholders may, by ordinary resolution, declare dividends but no such dividend shall exceed the amount recommended by the Directors. Under the laws of the Cayman Islands, our Company may pay a dividend out of either profit or share premium account; provided that in no circumstances may a dividend be paid out of our share premium if this would result in our Company being unable to pay its debts as they fall due in the ordinary course of business.
The holders of our Class A Ordinary Shares are entitled to such dividends as may be declared by our Board. The holders of our Class B Ordinary Shares have no rights to share in any dividends as may be declared by our Board. Our Memorandum and Articles of Association provide that dividends may be declared and paid out of the funds of our company lawfully available therefor. Under the laws of the Cayman Islands, our company may pay a dividend out of either profit or share premium account; provided that in no circumstances may a dividend be paid out of our share premium if this would result in our company being unable to pay its debts as they fall due in the ordinary course of business.
Subject to the Company’s Memorandum and Articles and any other sanction required by the Companies Act, each Class A Ordinary Share confers on the holder an equal share in the distribution of any surplus assets of the Company on its liquidation.
Voting Rights
Voting at any meeting of shareholders is by way of a poll duly demanded. Subject to the Companies Act, a poll may be demanded by:
| ● | by the chairman of the meeting; or |
| ● | by at least one shareholder present in person or by proxy or (in the case of a shareholder being a corporation) by its duly authorized representative having the right to vote on the resolutions. |
| 22 |
An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast at a meeting, while a special resolution requires the affirmative vote of no less than two-thirds of the votes cast attaching to the issued and outstanding ordinary shares at a meeting.
Subject to the Company’s Memorandum and Articles of Association, each Class A Ordinary Share confers on the holder the right to one (1) vote at a meeting of the shareholders or on any resolution of shareholders.
Subject to the Company’s Memorandum and Articles of Association, each Class B Ordinary Share confers on the holder the right to twenty (20) votes per share at a meeting of the shareholders or on any resolution of shareholders.
A special resolution will be required for important matters such as a change of name, making changes to our Memorandum and Articles of Association, a reduction of our share capital and the winding up of our company. Our shareholders may, among other things, divide or combine their shares by ordinary resolution.
An ordinary resolution to be passed at a meeting by the shareholders requires a simple majority of the votes cast by shareholders who (being entitled to do so) vote in person (or, in the case of corporations, by their duly authorized representatives) or by proxy at a meeting, while a special resolution requires a majority of not less than two-thirds of the votes cast by the shareholders who (being entitled to do so) vote in person (or, in the case of corporations, by their duly authorized representatives) or by proxy at a meeting. The expression of an ordinary resolution and a special resolution includes a unanimous written resolution. A special resolution will be required for important matters such as a change of name, making changes to our Memorandum and Articles, a reduction of our share capital and the winding up of our Company. Our shareholders may, among other things, divide or combine their shares by ordinary resolution.
In the case of an equality of votes, whether on a show of hands or on a poll, the chairman of the meeting at which the show of hands takes place or at which the poll is demanded, shall not be entitled to a second or casting vote.
Transfer of Shares
Subject to the restrictions set out below, any of our shareholders may transfer all or any of his or her Class A Ordinary Shares by an instrument of transfer in the usual or common form or in a form prescribed by NYSE or any other form approved by our Board. Notwithstanding the foregoing, Class A Ordinary Shares may also be transferred in accordance with the applicable rules and regulations of NYSE.
Where the Class A Ordinary Shares are not listed on or subject to the rules of NYSE American, our Board may, in its absolute discretion, decline to register any transfer of any Class A Ordinary Share which is not fully paid up or on which we have a lien. Our Board may also decline to register any transfer of any Class A Ordinary Share unless:
● the instrument of transfer is lodged with us, accompanied by the certificate for the Class A Ordinary Shares to which it relates and such other evidence as our Board may reasonably require to show the right of the transferor to make the transfer;
● the instrument of transfer is in respect of only one class of Class A Ordinary Shares;
● the instrument of transfer is properly stamped, if required;
● in the case of a transfer to joint holders, the number of joint holders to whom the Class A Ordinary Share is to be transferred does not exceed four; and
● a fee of such maximum sum as NYSE may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.
If our directors refuse to register a transfer they shall, within one month after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.
The registration of transfers may, on 14 days’ notice being given by advertisement in such one or more newspapers or by electronic means and after compliance with any notice required in accordance with the rules of NYSE American, be suspended and the register closed at such times and for such periods as our Board may from time to time determine; provided, however, that the registration of transfers shall not be suspended nor the register closed for more than 30 days in any year as our board may determine.
| 23 |
Liquidation Rights
If our company is wound up, the liquidator may with the sanction of a special resolution and any other sanction required by the Companies Act, divide in specie among the shareholders of the Class A Ordinary Shares the whole or any part of the assets of the Company and may, for that purpose, value any assets and to determine how the division shall be carried out as among the shareholders of the ordinary shares.
The liquidator may also vest the whole or any part of these assets in trustees for the benefit of the shareholders of Class A Ordinary Shares and those liable to contribute to the winding up.
No distribution (whether in cash or otherwise) of our company’s assets on a winding up may be made to a holder of a Class B Ordinary Share.
ENFORCEABILITY OF CIVIL LIABILITIES
For a description of enforceability of civil liabilities, please read “Item 10. Additional Information — 10.B. Memorandum and articles of association — Enforceability of Civil liabilities” in our annual report on Form 20-F for the fiscal year ended April 30, 2026, which is incorporated by reference into this prospectus. There have been no material changes or developments to the enforceability of civil liabilities, since the filing of our 2026 Annual Report, except as otherwise set forth in this prospectus.
PLAN OF DISTRIBUTION
The Class A Ordinary Shares offered by this prospectus are being offered by the Selling Shareholder, High West Partners LLC. The Purchase Shares and the Commitment Shares may be sold or distributed from time to time by the Selling Shareholder directly to one or more purchasers, or through brokers, dealers, or underwriters who may act solely as agents, at market prices prevailing at the time of sale, at prices related to the prevailing market prices, at negotiated prices, or at fixed prices, which may be changed. The sale of the Class A Ordinary Shares offered by this prospectus could be effected in one or more of the following methods: (i) ordinary brokerage transactions; (ii) transactions involving cross or block trades; (iii) through brokers, dealers, or underwriters who may act solely as agents; (iv) “at the market” into an existing market for the Class A Ordinary Shares; (v) in other ways not involving market makers or established trading markets, including direct sales to purchasers or sales effected through agents; (vi) in privately negotiated transactions; or (vii) any combination of the foregoing.
High West is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act in connection with the resales of the Class A Ordinary Shares under this prospectus. Any broker-dealers or agents that are involved in selling the Class A Ordinary Shares offered under this prospectus may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. Any discounts, commissions, concessions or profit they earn on any resale of the Class A Ordinary Shares may be deemed to be underwriting discounts and commissions under the Securities Act.
The Selling Shareholder has informed us that it may use one or more registered broker-dealers to effectuate resales, if any, of the Class A Ordinary Shares that it may acquire from us pursuant to the Purchase Agreement. Such resales will be made at prices and at terms then prevailing or at prices related to the then-current market price. Each such broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. The Selling Shareholder has informed us that each broker-dealer it may engage to effectuate resales of the Class A Ordinary Shares on its behalf may receive commissions from the Selling Shareholder for executing such resales and, if so, such commissions will not exceed customary brokerage commissions.
Other than the Purchase Agreement and the Registration Rights Agreement, we know of no existing arrangements between the Selling Shareholder and any other shareholder, broker, dealer, underwriter or agent relating to the sale or distribution of the Class A Ordinary Shares offered by this prospectus.
We will pay the expenses incurred in registering under the Securities Act the offer and resale of the Class A Ordinary Shares by the Selling Shareholder, including all registration and filing fees and the printing and legal fees and expenses allocated to us under the Registration Rights Agreement. The Selling Shareholder will bear all underwriting discounts and selling commissions, if any, and any other fees and expenses attributable to its sale of the Class A Ordinary Shares.
| 24 |
The Selling Shareholder has agreed that, during the term of the Purchase Agreement, neither it nor any of its agents, representatives or affiliates will, directly or indirectly, engage in any short sale of our Class A Ordinary Shares or any hedging transaction that establishes a net short position in our Class A Ordinary Shares, or otherwise violate Regulation SHO under the Exchange Act. The Selling Shareholder has also agreed to comply with the applicable provisions of Regulation M promulgated under the Exchange Act, which may limit the timing of purchases and sales of our Class A Ordinary Shares by the Selling Shareholder and any other person engaged in the distribution.
We and the Selling Shareholder have agreed to indemnify one another against certain liabilities in connection with the offering of the Class A Ordinary Shares offered hereby, including liabilities arising under the Securities Act.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
EXPENSES RELATING TO THIS OFFERING
Set forth below is an itemization of the total expenses that are expected to be incurred by us in connection with the Class A Ordinary Shares being registered for resale hereby and the offer and sale of the Class A Ordinary Shares by the Selling Shareholder. With the exception of the SEC registration fee, all amounts are estimates.
| SEC Registration Fee | $ | US$3,000 | ||
| Legal Fees and Expenses | $ | US$100,000 | ||
| Accounting Fees and Expenses | $ | US$21,100 | ||
| Transfer agent fees | $ | US$5,000 | ||
| Miscellaneous Expenses | $ | US$10,000 | ||
| Total Expenses | $ | US$139,100 |
LEGAL MATTERS
Loeb & Loeb LLP is acting as counsel to our company regarding U.S. securities law matters. The validity of the Class A Ordinary Shares offered hereby will be opined upon for us by Ogier. We can rely on Bayfront Law LLC regarding certain legal matters as to Singapore law. Greenberg Traurig, P.A. is acting as counsel to High West in connection with this offering.
EXPERTS
The consolidated financial statements as of April 30, 2025, and for the years ended April 30, 2025 and 2024 incorporated by reference in this prospectus have been audited by Kreit & Chiu CPA LLP, an independent registered public accounting firm, as stated in their report incorporated by reference herein. Such consolidated financial statements have been included in reliance upon the report of such firm given upon the authority of such firm as experts in accounting and auditing. The office of Kreit & Chiu CPA LLP is located at 733 Third Avenue, Floor 16 #1014, New York, NY 10017.
The consolidated financial statements as of April 30, 2026, and for the year ended April 30, 2026 incorporated by reference in this prospectus have been audited by AssentSure PAC, an independent registered public accounting firm, as stated in their report incorporated by reference herein. Such consolidated financial statements have been included in reliance upon the report of such firm given upon the authority of such firm as experts in accounting and auditing. The office of AssentSure PAC is located at 180B Bencoolen Street #03-01 The Bencoolen Singapore 189648 .
| 25 |
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
We are allowed to incorporate by reference the information we file with the SEC, which means that we can disclose important information to you by referring to those documents. The information incorporated by reference is considered to be part of this prospectus. We incorporate by reference in this prospectus the documents listed below:
| ● | our latest annual report on Form 20-F for the year ended April 30, 2026, filed with the SEC on August 31, 2026, as amended on November 18, 2026; and | |
| ● | our current reports on Form 6-K, furnished to the SEC on July 27, 2026, August 12, 2026, August 13, 2026, September 4, 2026, September 18, 2026, September 30, 2026, October 2, 2026 , October 19, 2026, and October 27, 2026. |
The information relating to us contained in this prospectus does not purport to be comprehensive and should be read together with the information contained in the documents incorporated or deemed to be incorporated by reference in this prospectus.
As you read the above documents, you may find inconsistencies in information from one document to another. If you find inconsistencies between the documents and this prospectus, you should rely on the statements made in the most recent document. All information appearing in this prospectus is qualified in its entirety by the information and financial statements, including the notes thereto, contained in the documents incorporated by reference herein.
Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those documents unless such exhibits are specially incorporated by reference in this prospectus, will be provided at no cost to each person, including any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to:
55 Ayer Rajah Crescent,
#05-05
Singapore 139949
Tel: +65 6224 6320
You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, or such earlier date, that is indicated in this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.
WHERE YOU CAN FIND MORE INFORMATION
We have filed with the SEC a registration statement on Form F-1, including relevant exhibits and schedules under the Securities Act, covering the Class A Ordinary Shares offered by this prospectus. You should refer to our registration statements and their exhibits and schedules if you would like to find out more about us and about the Class A Ordinary Shares. This prospectus summarizes material provisions of contracts and other documents that we refer you to. Since this prospectus may not contain all the information that you may find important, you should review the full text of these documents.
We are subject to periodic reporting and other informational requirements of the Exchange Act, as applicable to foreign private issuers. Accordingly, we are required to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our executive officers, directors and principal shareholders are exempt from short-swing profit recovery provisions contained in Section 16 of the Exchange Act.
The SEC maintains a website that contains reports and other information about issuers, such as us, who file electronically with the SEC. The address of that website is http://www.sec.gov. The information on that website is not a part of this prospectus.
No dealers, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus. You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date.
| 26 |
Phaos Technology Holdings (Cayman) Limited
406,808 CLASS A ORDINARY SHARES to be Sold by the Selling Shareholder
PROSPECTUS
_____________, 2026
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 6. Indemnification of Directors and Officers.
Cayman Islands law does not limit the extent to which a company’s articles of association may provide for indemnification of officers and Directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime.
Our Articles of Association provide that, to the extent permitted by law, we shall indemnify each existing or former secretary, director (including alternate director), and any of our other officers (including an investment adviser or an administrator or liquidator) and their personal representatives against:
(a) all actions, proceedings, costs, charges, expenses, losses, damages, or liabilities incurred or sustained by the existing or former director (including alternate director), secretary, or officer in or about the conduct of our business or affairs or in the execution or discharge of the existing or former director (including alternate director)’s, secretary’s, or officer’s duties, powers, authorities or discretions; and
(b) without limitation to paragraph (a) above, all costs, expenses, losses, or liabilities incurred by the existing or former director (including alternate director), secretary, or officer in defending (whether successfully or otherwise) any civil, criminal, administrative or investigative proceedings (whether threatened, pending or completed) concerning us or our affairs in any court or tribunal, whether in the Cayman Islands or elsewhere.
No such existing or former director (including alternate director), secretary, or officer, however, shall be indemnified in respect of any matter arising out of his own actual fraud, willful default, or willful neglect.
To the extent permitted by the Companies Act, we may make a payment, or agree to make a payment, whether by way of advance, loan or otherwise, for any legal costs incurred by an existing or former director (including alternate director), secretary, or any of our officers in respect of any matter identified above on condition that the director (including alternate director), secretary, or officer must repay the amount paid by us to the extent that we are ultimately found not liable to indemnify the director (including alternate director), secretary or that officer for those legal costs.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to Directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.
Item 7. Recent Sales of Unregistered Securities
Founding Transactions
The Company was incorporated in the Cayman Islands with limited liability on March 7, 2024. On March 7, 2024, the Company issued 1 fully-paid Class B Ordinary Share of par value US$0.0001 each to Ogier Global Subscriber (Cayman) Limited which was transferred to Beh Hook Seng on the same day.
Selling Shareholder Transactions
As part of the internal reorganization of the Company, on November 29, 2024, the Company issued (i) 298,625 Class A Ordinary Shares to ICHAM Master Fund VCC in consideration for its investment of US$643,000 into the Company, and (ii) 1,088,250 Class A Ordinary Shares to Liew Ah Choy in consideration for its investment of S$100,000 into the Company. On November 29, 2024, Chua Jun Hao, David, Chua Kheng Choon and Tan Chiew Hiah acquired 1,000,000 Class A Ordinary Shares, 587,625 Class A Ordinary Shares, and 587,625 Class A Ordinary Shares, respectively, at par value, from TongHuai SG Enterprise Pte. Ltd for various services rendered to the Company.
None of the offerees is a U.S. person. These transactions were not registered under the Securities Act in reliance on an exemption from registration set forth in Regulation S thereof.
Item 8. Exhibits and Financial Statement Schedules
(a) Exhibits
See Exhibit Index beginning on page II-3 of this registration statement.
The agreements included as exhibits to this registration statement contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties were made solely for the benefit of the other parties to the applicable agreement and (i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) may have been qualified in such agreement by disclosure that was made to the other party in connection with the negotiation of the applicable agreement; (iii) may apply contract standards of “materiality” that are different from “materiality” under the applicable securities laws; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement.
We acknowledge that, notwithstanding the inclusion of the foregoing cautionary statements, we are responsible for considering whether additional specific disclosure of material information regarding material contractual provisions is required to make the statements in this registration statement not misleading.
(b) Financial Statement Schedules
Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated Financial Statements or the Notes thereto.
| II-1 |
Item 9. Undertakings
The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.
The undersigned registrant hereby undertakes:
| 1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |
| (i) | To include any prospectus required by section 10(a)(3) of the Securities Act of 1933; |
| (ii) | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (§230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement. |
| (iii) | To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. |
| 2) | That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| 3) | To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
| 4) | To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment, financial statements required pursuant to this paragraph and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial statements. |
| 5) | That, for the purpose of determining any liability under the Securities Act of 1933 to any purchaser, each prospectus filed by the Registrant pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use; |
| 6) | That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities: |
The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the placement method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:
| (i) | Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424. | |
| (ii) | Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; | |
| (iii) | The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and | |
| (iv) | Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. |
| 7) | Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to Directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the U.S. Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a Director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such Director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. |
| 8) | That, for purposes of determining any liability under the Securities Act of 1933, (i) the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective; and (ii) each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. |
| II-2 |
EXHIBIT INDEX
| Exhibit No. | Description | |
| 3.1* | Third Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 1.1 to the Company’s Report on Form 6-K furnished to the SEC on October 2, 2026) | |
| 5.1† | Opinion of Ogier regarding the validity of the Class A Ordinary Shares being registered | |
| 10.1* | Securities Purchase Agreement, dated as of September 28, 2026, by and between the Company and High West Partners LLC (incorporated by reference to Exhibit 10.1 to the Company’s Report on Form 6-K furnished to the SEC on September 30, 2026) | |
| 10.2* | Registration Rights Agreement, dated as of September 28, 2026, by and between the Company and High West Partners LLC (incorporated by reference to Exhibit 10.2 to the Company’s Report on Form 6-K furnished to the SEC on September 30, 2026) | |
| 23.1† | Consent of AssentSure PAC, independent registered public accounting firm | |
| 23.2† | Consent of Kreit & Chiu CPA LLP, independent registered public accounting firm | |
| 23.3† | Consent of Ogier (included in Exhibit 5.1) | |
| 24.1† | Power of Attorney (included on the signature page hereto) | |
| 107† | Filing Fee Table |
| * | Previously filed |
| † | Filed herewith |
| II-3 |
SIGNATURES
Pursuant to the requirements of the Securities Act, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Singapore, on November 20, 2026.
| By: | /s/ Gan Hong Loon | |
| Name: | Gan Hong Loon | |
| Title: | Director, Chief Financial Officer, and Interim Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Gan Hong Loon, each acting singly as an attorney-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act of 1933, as amended (the “Securities Act”), and any rules, regulations and requirements of the U.S. Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of ordinary shares of the registrant (the “Shares”), including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form F-1 (the “Registration Statement”) to be filed with the U.S. Securities and Exchange Commission with respect to such Shares, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement; and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
| Signatures | Title | Date | ||
| Beh Hook Seng | November 20, 2026 | |||
| /s/ Beh Hook Seng | Chairman and Executive Director (Principal Executive Officer) |
|||
| Gan Hong Loon | November 20, 2026 | |||
| /s/ Gan Hong Loon | Director, Chief Financial Officer, and Interim Chief Executive Officer | |||
| (Principal Accounting and Financial Officer) | ||||
| Lionel Choong Khuat Leok | November 20, 2026 | |||
| /s/ Lionel Choong Khuat Leok | Independent Director | |||
| Wesley Yiu | November 20, 2026 | |||
| /s/ Wesley Yiu | Independent Director | |||
| Liu Yi, Louis | November 20, 2026 | |||
| /s/ Liu Yi, Louis | Independent Director | |||
| Erik Cheong Wei Keat | November 20, 2026 | |||
| /s/ Erik Cheong Wei Keat | Independent Director | |||
| Koh Boon Chiao | November 20, 2026 | |||
| /s/ Koh Boon Chiao | Independent Director |
SIGNATURE OF AUTHORIZED REPRESENTATIVE OF THE REGISTRANT
Pursuant to the Securities Act, the undersigned, the duly authorized representative in the United States of America, has signed this registration statement or amendment thereto in New York, New York, United States of America on November 20, 2026.
| COGENCY GLOBAL INC. | ||
| By: | /s/ Colleen A. De Vries | |
| Name: | Colleen A. De Vries | |
| Title: | Senior Vice-President on behalf of Cogency Global Inc. | |
| II-4 |